INCB123667
- Generic Name
- INCB123667
Innovent Biologics to Present Breakthrough Clinical Data for IBI363 PD-1/IL-2 Bispecific Antibody at ASCO 2025
• Innovent Biologics will showcase seven oral presentations at ASCO 2025, featuring breakthrough clinical data for its novel PD-1/IL-2α-bias bispecific antibody IBI363 in melanoma, colorectal cancer, and non-small cell lung cancer.
• IBI343, Innovent's anti-CLDN18.2 antibody-drug conjugate, secured an oral presentation slot for its Phase 1b data in pancreatic cancer, demonstrating promising potential in this difficult-to-treat malignancy.
• The company's robust pipeline of bispecific antibodies and ADCs highlights Innovent's growing position as a leader in the "IO+ADC" space, with multiple candidates advancing toward pivotal-stage development.
Incyte Reports Strong 2024 Growth with $4.2B Revenue, Outlines Ambitious 2025 Pipeline Milestones
• Incyte achieved total revenues of $4.2 billion in 2024, marking a 15% year-over-year growth, driven by strong performance of Jakafi ($2.8B) and Opzelura ($508M).
• The company anticipates four new product launches in 2025, including Niktimvo for chronic GVHD and expanded indications for existing therapies in atopic dermatitis and lymphoma.
• Incyte's R&D pipeline shows significant advancement with plans for four pivotal study readouts, three Phase 3 study initiations, and seven proof-of-concept study results expected in 2025.
Oncolytics Biotech's Pelareorep Shows Promise in Breast Cancer Treatment, Fueling Optimism in Oncology
• Oncolytics Biotech's BRACELET-1 trial showed pelareorep, combined with paclitaxel, significantly improved survival rates in HR+/HER2- advanced or metastatic breast cancer patients.
• The median overall survival for patients treated with pelareorep was not reached, with estimates suggesting a 32-month survival benefit compared to 18 months for the control arm.
• Incyte's CDK2 inhibitor INCB123667 demonstrated clinical activity in patients with advanced solid tumors, particularly platinum-resistant ovarian cancer, showing a 24.3% overall response rate.
• Regeneron presented five-year survival data for Libtayo as a first-line monotherapy in advanced non-small cell lung cancer, reinforcing its role as a key component in oncology treatment.
Incyte's Zynyz Shows Promise in Frontline Anal Cancer Treatment
• Incyte's Zynyz, combined with chemotherapy, significantly reduced the risk of disease progression or death in patients with squamous cell carcinoma of the anal canal (SCAC).
• The POD1UM-303 trial demonstrated a 37% reduction in disease progression or death and extended median progression-free survival to 9.3 months compared to chemotherapy alone.
• Zynyz also showed a trend towards improved overall survival, with a 30% improvement compared to the control group, potentially establishing it as a new standard of care.
• Incyte's CDK2 inhibitor, INCB123667, also demonstrated activity against various solid tumors, particularly ovarian cancer, with a phase 3 program planned for 2025.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath